| 1 |
34614211 | The cure of leukemia through the optimist's prism. | 2022 Jan 15 |
1 |
| 2 |
34699069 | Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model-Informed Dose Selection for Pediatric Development. | 2022 Apr |
1 |
| 3 |
35057108 | BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia. | 2022 Jan 17 |
1 |
| 4 |
35172577 | Discovery of Anticancer Hybrid Molecules by Supervised Machine Learning Models and in Vitro Validation in Drug Resistant Chronic Myeloid Leukemia Cells. | 2022 Feb 28 |
1 |
| 5 |
35412404 | Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia. | 2022 May |
1 |
| 6 |
35544670 | An evaluation of ponatinib as a therapy in adult patients with resistant/intolerant chronic-phase chronic myeloid leukemia. | 2022 May |
1 |
| 7 |
35551463 | BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro. | 2022 May 13 |
1 |
| 8 |
33107354 | Ponatinib is a potential therapeutic approach for malignant pleural mesothelioma. | 2021 Feb |
3 |
| 9 |
33748144 | The Discovery of Novel BCR-ABL Tyrosine Kinase Inhibitors Using a Pharmacophore Modeling and Virtual Screening Approach. | 2021 |
1 |
| 10 |
33774681 | The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study. | 2021 Jul |
1 |
| 11 |
33796468 | Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase. | 2021 |
2 |
| 12 |
33907977 | Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute. | 2021 Aug |
1 |
| 13 |
34117218 | IMiDs uniquely synergize with TKIs to upregulate apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells expressing a dominant-negative IKZF1 isoform. | 2021 Jun 11 |
1 |
| 14 |
34276365 | Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts. | 2021 |
1 |
| 15 |
34659899 | Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations. | 2021 |
5 |
| 16 |
34959482 | The TKI Era in Chronic Leukemias. | 2021 Dec 20 |
1 |
| 17 |
30661457 | How does the novel T315L mutation of breakpoint cluster region-abelson (BCR-ABL) kinase confer resistance to ponatinib: a comparative molecular dynamics simulation study. | 2020 Jan |
5 |
| 18 |
31925328 | A combined computational and experimental strategy identifies mutations conferring resistance to drugs targeting the BCR-ABL fusion protein. | 2020 Jan 9 |
1 |
| 19 |
32095692 | Nicotinamide-Ponatinib Analogues as Potent Anti-CML and Anti-AML Compounds. | 2020 Feb 18 |
2 |
| 20 |
32175644 | Renovascular hypertension from the BCR-ABL tyrosine kinase inhibitor ponatinib. | 2020 Apr |
1 |
| 21 |
32829325 | Further Analytical, Pharmacokinetic, and Clinical Observations on Low-Dose Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. | 2020 |
1 |
| 22 |
33419251 | Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation. | 2020 Dec 20 |
1 |
| 23 |
33460055 | Dynamic evolution of ponatinib-resistant mutations in BCR-ABL1-positive leukaemias revealed by next-generation sequencing. | 2020 Dec |
1 |
| 24 |
30580670 | Predictive models for designing potent tyrosine kinase inhibitors in chronic myeloid leukemia for understanding its molecular mechanism of resistance by molecular docking and dynamics simulations. | 2019 Nov |
2 |
| 25 |
30705592 | Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies. | 2019 |
3 |
| 26 |
31115499 | PF‑114, a novel selective inhibitor of BCR‑ABL tyrosine kinase, is a potent inducer of apoptosis in chronic myelogenous leukemia cells. | 2019 Jul |
2 |
| 27 |
31510844 | Ponatinib use in two pediatric patients with relapsed Ph + ALL with ABL1 kinase domain mutations. | 2019 Nov |
1 |
| 28 |
29165716 | Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition. | 2018 May 1 |
4 |
| 29 |
29358661 | Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant. | 2018 Jan 22 |
1 |
| 30 |
29434033 | PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. | 2018 May 17 |
1 |
| 31 |
29608815 | Alkynylnicotinamide-Based Compounds as ABL1 Inhibitors with Potent Activities against Drug-Resistant CML Harboring ABL1(T315I) Mutant Kinase. | 2018 Jun 20 |
2 |
| 32 |
29675611 | Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. | 2018 Sep |
1 |
| 33 |
29675955 | Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications. | 2018 Jun |
1 |
| 34 |
29899872 | Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells. | 2018 May 29 |
1 |
| 35 |
30024740 | Multiplexed Quantitative MALDI MS Approach for Assessing Activity and Inhibition of Protein Kinases Based on Postenrichment Dephosphorylation of Phosphopeptides by Metal-Organic Framework-Templated Porous CeO2. | 2018 Aug 21 |
1 |
| 36 |
30069627 | Ponatinib: A Third-Generation Inhibitor for the Treatment of CML. | 2018 |
2 |
| 37 |
30217442 | BCR-ABL tyrosine kinase inhibition induces metabolic vulnerability by preventing the integrated stress response in K562 cells. | 2018 Oct 12 |
1 |
| 38 |
30238007 | Ponatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylation. | 2018 |
2 |
| 39 |
31249931 | BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis? | 2018 Jan |
1 |
| 40 |
27696211 | The Myocyte-Damaging Effects of the BCR-ABL1-Targeted Tyrosine Kinase Inhibitors Increase with Potency and Decrease with Specificity. | 2017 Jul |
1 |
| 41 |
27761606 | BCR-ABL-positive acute myeloid leukemia: About one case treated with ponatinib. | 2017 Feb |
1 |
| 42 |
27852118 | Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. | 2017 Jan |
1 |
| 43 |
27864605 | Erratum to: BCR-ABL-positive acute myeloid leukemia: About one case treated with ponatinib. | 2017 Feb |
1 |
| 44 |
28184964 | Absorption, metabolism, and excretion of [14C]ponatinib after a single oral dose in humans. | 2017 Mar |
1 |
| 45 |
28278078 | Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression. | 2017 Apr 3 |
1 |
| 46 |
28427224 | Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells. | 2017 May 9 |
1 |
| 47 |
29050692 | Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia? | 2017 Sep |
1 |
| 48 |
26479578 | In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study. | 2016 Oct |
1 |
| 49 |
26607600 | Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML. | 2016 Apr 15 |
1 |
| 50 |
26864341 | Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. | 2016 Apr 28 |
2 |